IP Library › Patent Application 15036649
Patent Application
App. No. 15/036,649

COMPOSITIONS COMPRISING HUMAN PLACENTAL PERFUSATE CELLS, SUBPOPULATIONS THEREOF, AND THEIR USES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/036,649
Abstract

Provided herein are compositions comprising mononuclear cells from human placental perfusate and methods of using such cells, including using the cells together with hematopoietic cells, for example to establish chimerism, reduce the severity or duration of graft versus host disease, treat or ameliorate symptoms of sarcopenia, metabolic disorders and hematologic disorders, such as hematologic malignancies, and treat or ameliorate symptoms of ischemic encephalopathy (e.g., hypoxic ischemic encephalopathy) and other central nervous system injuries.

Claims (68)

1 . A composition comprising isolated human placental perfusate, wherein the human placental perfusate comprises at least 6×10 5 CD34 + cells.

2 . The composition of claim 1 , wherein the composition further comprises a 2-fold greater number of CD34 + cells.

3 . The composition of claim 1 , wherein the composition further comprises a 10-fold greater number of CD34 + cells.

4 . The composition of claim 1 , wherein the composition further comprises a 50-fold greater number of CD34 + cells.

5 . The composition of claim 1 , wherein the composition comprises substantially pure human placental perfusate CD34 + cells.

6 . A composition comprising isolated human placental perfusate, wherein the human placental perfusate comprises at least 5×10 5 CD34 + CD45 − cells.

7 . The composition of claim 6 , wherein the composition further comprises a 2-fold greater number of CD34 + CD45 − cells.

8 . The composition of claim 6 , wherein the composition further comprises a 10-fold greater number of CD34 + CD45 − cells.

9 . The composition of claim 6 , wherein the composition further comprises a 50-fold greater number of CD34 + CD45 − cells.

10 . The composition of claim 6 , wherein the composition comprises substantially pure human placental perfusate CD34 + CD45 − cells.

11 . A composition comprising isolated human placental perfusate, wherein the human placental perfusate comprises at least 6×10 5 CD34 + CD31 + cells.

12 . The composition of claim 11 , wherein the composition further comprises a 2-fold greater number of CD34 + CD31 + cells.

13 . The composition of claim 11 , wherein the composition further comprises a 10-fold greater number of CD34 + CD31 + cells.

14 . The composition of claim 11 , wherein the composition further comprises a 50-fold greater number of CD34 + CD31 + cells.

15 . The composition of claim 11 , wherein the composition comprises substantially pure human placental perfusate CD34 + CD31 + cells.

16 . A composition comprising isolated human placental perfusate, wherein the human placental perfusate comprises at least 5×10 5 CD34 + KDR + cells.

17 . The composition of claim 16 , wherein the composition further comprises a 2-fold greater number of CD34 + KDR + cells.

18 . The composition of claim 16 , wherein the composition further comprises a 10-fold greater number of CD34 + KDR + cells.

19 . The composition of claim 16 , wherein the composition further comprises a 50-fold greater number of CD34 + KDR + cells.

20 . The composition of claim 16 , wherein the composition comprises substantially pure human placental perfusate CD34 + KDR + cells.

21 . A composition comprising isolated human placental perfusate, wherein the human placental perfusate comprises at least 5×10 5 CD34 + CXCR4 + cells.

22 . The composition of claim 21 , wherein the composition further comprises a 2-fold greater number of CD34 + CXCR4 + cells.

23 . The composition of claim 21 , wherein the composition further comprises a 10-fold greater number of CD34 + CXCR4 + cells.

24 . The composition of claim 21 , wherein the composition further comprises a 50-fold greater number of CD34 + CXCR4 + cells.

25 . The composition of claim 21 , wherein the composition comprises substantially pure human placental perfusate CD34 + CXCR4 + cells.

26 . A composition comprising isolated human placental perfusate, wherein the human placental perfusate comprises at least 6×10 5 CD34 + CD38 − cells.

27 . The composition of claim 26 , wherein the composition further comprises a 2-fold greater number of CD34 + CD38 − cells.

28 . The composition of claim 26 , wherein the composition further comprises a 10-fold greater number of CD34 + CD38 − cells.

29 . The composition of claim 26 , wherein the composition further comprises a 50-fold greater number of CD34 + CD38 − cells.

30 . The composition of claim 26 , wherein the composition comprises substantially pure human placental perfusate CD34 + CD38 − cells.

31 . A composition comprising isolated human placental perfusate, wherein the human placental perfusate comprises at least 7×10 5 CD34 + CD117 − cells.

32 . The composition of claim 31 , wherein the composition further comprises a 2-fold greater number of CD34 + CD117 − cells.

33 . The composition of claim 31 , wherein the composition further comprises a 10-fold greater number of CD34 + CD117 − cells.

34 . The composition of claim 31 , wherein the composition further comprises a 50-fold greater number of CD34 + CD117 − cells.

35 . The composition of claim 31 , wherein the composition comprises substantially pure human placental perfusate CD34 + CD117 − cells.

36 . A composition comprising isolated human placental perfusate, wherein the human placental perfusate comprises at least 6×10 5 CD34 + CD140a + cells.

37 . The composition of claim 36 , wherein the composition further comprises a 2-fold greater number of CD34 + CD140a + cells.

38 . The composition of claim 36 , wherein the composition further comprises a 10-fold greater number of CD34 + CD140a + cells.

39 . The composition of claim 36 , wherein the composition further comprises a 50-fold greater number of CD34 + CD140a + cells.

40 . The composition of claim 36 , wherein the composition comprises substantially pure human placental perfusate CD34 + CD140a + cells.

41 . A composition comprising isolated human placental perfusate, wherein the human placental perfusate comprises at least 3×10 5 CD34 + Nestin + cells.

42 . The composition of claim 40 , wherein the composition further comprises a 2-fold greater number of CD34 + Nestin + cells.

43 . The composition of claim 40 , wherein the composition further comprises a 10-fold greater number of CD34 + Nestin + cells.

44 . The composition of claim 40 , wherein the composition further comprises a 50-fold greater number of CD34 + Nestin + cells.

45 . The composition of claim 40 , wherein the composition is substantially pure human placental perfusate CD34 + Nestin + cells.

46 . A composition comprising isolated human placental perfusate, wherein the human placental perfusate comprises at least 3×10 4 CD3 + CD4 + CD8 − CD25 hi CD127 low cells.

47 . The composition of claim 46 , wherein the composition further comprises a 2-fold greater number of CD3 + CD4 + CD8 − CD25 hi CD127 low cells.

48 . The composition of claim 46 , wherein the composition further comprises a 10-fold greater number of CD3 + CD4 + CD8 − CD25 hi CD127 low cells.

49 . The composition of claim 46 , wherein the composition further comprises a 50-fold greater number of CD3 + CD4 + CD8 − CD25 hi CD127 low cells.

50 . The composition of claim 46 , wherein the composition is substantially pure human placental perfusate CD3 + CD4 + CD8 − CD25 hi CD127 low cells.

51 . The composition of any one of claims 1 to 50 , wherein the human placental perfusate has been isolated from perfusion of a single placenta.

52 . A method of treating a central nervous system injury, disease, or disorder in a subject, comprising administering to the subject the composition of any one of claims 1 to 50 and hematopoietic cells from another source.

53 . The method of claim 52 , wherein said central nervous system injury, disease, or disorder is hypoxic ischemic encephalopathy.

54 . A method of treating sarcopenia in a subject, comprising administering to the subject the composition of any one of claims 1 to 50 and hematopoietic cells from another source.

55 . A method of inducing chimerism in a subject, comprising administering to the subject the composition of any one of claims 1 to 50 and hematopoietic cells from another source.

56 . A method for cell engraftment in a subject, comprising administering to the subject the composition of any one of claims 1 to 50 and hematopoietic cells from another source.

57 . A method for reducing the duration or severity of graft versus host disease (GVHD) in a subject, comprising administering to the subject the composition of any one of claims 1 to 50 and hematopoietic cells from another source.

58 . A method of treating a metabolic disorder in a subject, comprising administering to the subject the composition of any one of claims 1 to 50 and hematopoietic cells from another source.

59 . A method of treating a hematologic disorder or malignancy in a subject, comprising administering to the subject the composition of any one of claims 1 to 50 and hematopoietic cells from another source.

60 . A composition as defined in any one of claims 1 to 50 for use in a method:

(a) of treatment of a central nervous system injury, disease, or disorder in a subject, preferably said central nervous system injury, disease, or disorder is hypoxic ischemic encephalopathy;

(b) of inducing chimerism in a subject;

(c) for cell engraftment;

(d) for reducing the duration or severity of graft versus host disease (GVHD) in a subject;

(e) of treating a metabolic disorder in a subject;

(f) of treating a hematologic disorder or malignancy in a subject; or

(g) of treating sarcopenia in a subject.

61 . The composition for use of claim 60 , wherein the composition further comprises hematopoietic cells from another source.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2017
From: CLARITY ACQUISITION II LLC
To: CELULARITY, INC.
Reel/Frame 044780/0261 →
MERGER Recorded Nov 8, 2017
From: ANTHROGENESIS CORPORATION
To: CLARITY ACQUISITION II LLC
Reel/Frame 044413/0680 →